Synthetic biotechnology company Amyris Inc. has filed for a Chapter 11 bankruptcy and plans to sell its consumer brands and focus on developing its sustainable ingredients business.
The Emeryville, CA-based firm announced on 9 August it has secured a commitment through its existing lender Foris Ventures for $190m of debtor-in-possession